0001209191-18-028866.txt : 20180509 0001209191-18-028866.hdr.sgml : 20180509 20180509162415 ACCESSION NUMBER: 0001209191-18-028866 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180507 FILED AS OF DATE: 20180509 DATE AS OF CHANGE: 20180509 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SARGEN GREGORY CENTRAL INDEX KEY: 0001227835 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10638 FILM NUMBER: 18818640 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CAMBREX CORP CENTRAL INDEX KEY: 0000820081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222476135 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MEADOWLANDS PLZ CITY: E RUTHERFORD STATE: NJ ZIP: 07073 BUSINESS PHONE: 2018043000 MAIL ADDRESS: STREET 1: ONE MEADOWLANDS PLAZA CITY: E. RUTHERFORD STATE: NJ ZIP: 07073 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-05-07 0 0000820081 CAMBREX CORP CBM 0001227835 SARGEN GREGORY ONE MEADOWLANDS PLAZA EAST RUTHERFORD NJ 07073 0 1 0 0 EVP, Corporate Development Common Stock 2018-05-07 4 A 0 30000 0.00 A 50000 D Common Stock 2018-05-07 4 S 0 23002 49.4618 D 26998 D Common Stock 2018-05-08 4 A 0 7500 16.905 A 34498 D Common Stock 2018-05-08 4 A 0 7500 17.81 A 41998 D Common Stock 2018-05-08 4 A 0 15000 41.36 A 56998 D Common Stock 2018-05-08 4 A 0 7500 40.65 A 64498 D Common Stock 2018-05-08 4 S 0 10565 49.05 D 53933 D Common Stock 2018-05-08 4 S 0 33933 49.6254 D 20000 D Stock Option (right to buy) 16.905 2018-05-08 4 M 0 7500 0.00 A 2020-10-28 Common Stock 7500 0 D Stock Option (right to buy) 17.81 2018-05-08 4 M 0 7500 0.00 A 2021-10-22 Common Stock 7500 7500 D Stock Option (right to buy) 41.36 2018-05-08 4 M 0 15000 0.00 A 2022-10-21 Common Stock 15000 15000 D Stock Option (right to buy) 40.65 2018-05-08 4 M 0 7500 0.00 A 2023-10-26 Common Stock 7500 22500 D Pursuant to settlement of a performance share award. Broker-assisted sale of which 14,805 shares were to cover the payment of withholding tax liability from the settlement of a performance share award. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.20 to $49.875 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.50 to $49.45 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 4 to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.50 to $49.85 inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 5 to this Form 4. The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 28, 2014, which was the first anniversary of the date on which the option was granted. The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 22, 2015, which was the first anniversary of the date on which the option was granted. The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 22, 2016, which was the first anniversary of the date on which the option was granted. The option representing a right to purchase 30,000 shares became exercisable in four equal installments beginning October 26, 2017, which was the first anniversary of the date on which the option was granted. Danielle Mann for Gregory Sargen by POA 2018-05-09